Athenex’s clinical pipeline includes small molecule, biologic, and cell therapies for the treatment of cancer.

ProgramDrug CandidateIndicationPre-ClinicalPhase 1Phase 2Phase 3Stage
Src Kinase InhibitionKlisyri® (tirbanibulin ointment)Actinic keratosis
FDA Approved
Phase 3 — FDA Approved
OrascoveryOral paclitaxel + encequidarMetastatic breast cancer
RECEIVED CRL FROM FDA
Phase 3 — RECEIVED CRL FROM FDA
OrascoveryOral paclitaxel + encequidarAngiosarcoma
Phase 2
OrascoveryOral paclitaxel + encequidar w/ dostarlimab*Neoadjuvant breast cancer
(I-SPY 2)
Phase 2
OrascoveryOral paclitaxel + encequidar w/ ramucirumab**Gastric cancer
Phase 1
OrascoveryOral paclitaxel + encequidar w/ pembrolizumabSolid tumors
Phase 1
OrascoveryOral docetaxel + encequidarSolid tumors
Phase 1
OrascoveryOral irinotecan + encequidarSolid tumors
Phase 1
OrascoveryOral eribulin + encequidarSolid tumors
Phase 1
Cell TherapyTCRT-ESO-A2Multiple tumors
Phase 1
Cell TherapyKUR-501 – GD2 autologous CAR-NKTNeuroblastoma
Phase 1
Cell TherapyKUR-502 – CD19 allogeneic CAR-NKTR/R lymphoma and leukemia
Phase 1
Cell TherapyKUR-503 – GPC3 allogeneic CAR-NKTHepatocellular Carcinoma
Pre-Clinical
Arginase Deprivation TherapyPT01Multiple tumors
Phase 1
* Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline
** Collaboration with Eli Lilly and Company, makers of ramucirumab

For more information about our trials, please visit clinicaltrials.gov.